Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O43826
UPID:
G6PT1_HUMAN
Alternative names:
Glucose-5-phosphate transporter; Glucose-6-phosphate translocase; Solute carrier family 37 member 4; Transformation-related gene 19 protein
Alternative UPACC:
O43826; O96016; Q5J7V4; Q9UI19; Q9UNS4
Background:
The Glucose-6-phosphate exchanger SLC37A4, also known as Glucose-5-phosphate transporter and Glucose-6-phosphate translocase, plays a pivotal role in glucose homeostasis. It functions as an inorganic phosphate and glucose-6-phosphate antiporter in the endoplasmic reticulum, crucial for glycogenolysis and gluconeogenesis processes.
Therapeutic significance:
SLC37A4's dysfunction is linked to metabolic disorders such as Glycogen storage disease types 1B, 1C, and 1D, and Congenital disorder of glycosylation 2W, characterized by hypoglycemia, hepatomegaly, and growth retardation. Targeting SLC37A4 could offer novel therapeutic avenues for these conditions.